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D Farge1,15, RK Burt2,15, M-C Oliveira3, E Mousseaux4, M Rovira5, Z Marjanovic6, J de Vries-Bouwstra7, N Del Papa8, R Saccardi9,16,
SJ Shah10, DC Lee10, C Denton11, T Alexander12, DG Kiely13,18 and JA Snowden14,16,18 for the EBMT ADWP Scleroderma Working
Group and on behalf of the Joint Accreditation Committee of the International Society for Cellular Therapy (JACIE) & European Society
for Blood and Marrow Transplantation (EBMT)17
Systemic sclerosis (SSc) is a rare disabling autoimmune disease with a similar mortality to many cancers. Two randomized controlled
trials of autologous hematopoietic stem cell transplantation (AHSCT) for SSc have shown signiﬁcant improvement in organ
function, quality of life and long-term survival compared to standard therapy. However, transplant-related mortality (TRM) ranged
from 3–10% in patients undergoing HSCT. In SSc, the main cause of non-transplant and TRM is cardiac related. We therefore
updated the previously published guidelines for cardiac evaluation, which should be performed in dedicated centers with expertize
in HSCT for SSc. The current recommendations are based on pre-transplant cardiopulmonary evaluations combining pulmonary
function tests, echocardiography, cardiac magnetic resonance imaging and invasive hemodynamic testing, initiated at
Northwestern University (Chicago) and subsequently discussed and endorsed within the EBMT ADWP in 2016.
Bone Marrow Transplantation advance online publication, 22 May 2017; doi:10.1038/bmt.2017.56
INTRODUCTION
Systemic sclerosis (SSc) is a rare and heterogeneous autoimmune
disease of unknown origin, with an incidence of 1 in 100 000.1 It is
characterized by skin and visceral (lung, gastrointestinal, cardio-
vascular and renal) ﬁbrosis secondary to excessive collagen
deposition with a limited cutaneous (lc) and a diffuse cutaneous
(dc) form.2 Rapidly progressive dc-SSc within the ﬁrst 4 years of
disease onset, observed in 10–20% of cases, is a life-threatening
condition, with a 3–5 year survival between 50 and 70%,3,4 the
main cause of death being cardiac related.5,6 Numerous other
factors have been reported to adversely reﬂect survival including
extensive skin thickening (measured by the modiﬁed Rodnan skin
score),7 altered functional status (measured using the Self Health
Assessment Questionnaire), altered renal function (presence of
either hypertension, proteinuria, urinary casts having excluded
non-SSc speciﬁc causes) or lung involvement (reﬂected in
abnormal lung function or CT appearances) and older age at
onset.8–11 Recently, more sensitive cardiac evaluations indicate
that some of these adverse prognostic factors may be associated
with markers of cardiac involvement. Pulmonary arterial hyperten-
sion (PAH) and pulmonary ﬁbrosis12,13 are also common causes of
death. While hypoxemic respiratory failure may occur, the
penultimate cause of death from PAH or interstitial lung disease
(ILD) is often not suffocation per se, that is, inability to oxygenate
blood, but rather cardiac failure in many patients.
Standard therapy with daily oral or monthly intravenous
cyclophosphamide regimens in SSc has demonstrated only
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limited beneﬁt.14,15 In contrast, early phase II trials16,17 and the
randomized controlled ASSIST18 followed by the large European
ASTIS phase III trials in SSc19 have shown that AHSCT using a
high-dose cyclophosphamide regimen signiﬁcantly improved
forced vital capacity, decreased diseased-lung volume, and that
SSc ILD might be partially reversed with continued improvement
in lung function for at least 2 years after transplantation.18–20
The presence of extensive lung disease or of speciﬁc cardiac
involvement in patients undergoing AHSCT is associated with an
increased transplant-related mortality (TRM), reﬂecting concerns
that cardiac impairment or impaired respiratory function may
directly or indirectly compromise cardiac function21 and translate
into high TRM due to inability to cope with complications. Due to
direct cardiotoxicity of drugs, transplant-related fever, neutropenic
infection and to saline overload during AHSCT, an extensive
cardiac evaluation to exclude PAH and primary or secondary
SSc-related cardiac involvement and constrictive pericarditis is
essential to reduce the risk of TRM22 and to provide an acceptable
risk-beneﬁt ratio of AHSCT.21
The aim of these guidelines is to summarize the current
evidence-based practices and to make recommendations as to
how TRM from AHSCT may be minimized through multi-
professional collaboration, careful patient selection, optimized
treatment regimens and audit of outcomes. This cardiopulmonary
guidelines process was initiated to update previous consensus23
after 10 years of additional international experience, as initiated at
Northwestern University (Chicago)21 and subsequently discussed
and endorsed within the European Society for Blood and Marrow
Transplantation (EBMT)-Autoimmune Disease Working Party
(ADWP) in 2016.
CARDIOPULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS
Cardiac complications
In early stages of disease, cardiac impairment is clinically
underappreciated and often overlooked by standard echocardio-
graphic reporting of gross wall motion abnormalities and left
ventricular ejection fraction (LVEF).24 Relying on LVEF alone can be
misleading, since SSc hearts may have a restrictive or constrictive
physiology with relatively intact LVEF, but signiﬁcant diastolic
dysfunction.22,25,26 As the disease may be clinically silent for a long
time, clinical studies only report a 10–61% prevalence of cardiac
involvement by using transthoracic echocardiography (TTE) as a
screening tool,5,27 while it ranges between 50 and 81% in autopsy-
based studies of SSc.28,29 In the EUSTAR database concerning 7073
patients,26 LVEF was estimated by TTE using Simpson’s method
and the prevalence of LVEFo55% was 5.4%. In contrast, a high
prevalence of reduced left ventricle (LV) and/or right ventricle (RV)
contractility in SSc patients despite a normal LVEF was detected
when more sophisticated tools were used, such as tissue Doppler
or cardiac magnetic resonance (CMR) imaging.
Ferri et al.8 reported 36% of SSc deaths related to cardiac
disease alone, and a recent literature search,6 comprising a total of
12 829 SSc patients from 18 cohort studies, found that causes of
death were 19.7% cardiac and 13.1% pulmonary hypertension,
and the risk of death was increased in patients with cardiac
involvement (hazard ratio (HR) 3.15)) and with PAH (HR 3.50). In
daily clinical practice, cardiac evaluation of SSc patients is based
on the results from clinical examination, electrocardiography
(ECG) and TTE, and in the presence of palpitations or abnormal-
ities on ECG, on 24 h Holter monitoring. B-type natriuretic peptide
(BNP) or N-terminal pro-BNP can be elevated as a marker of
myocardial stress usually reﬂecting the presence of right heart
failure or PAH.30
Pulmonary artery hypertension
Pulmonary hypertension (PH) is deﬁned at right heart catheteriza-
tion (RHC) as a mean pulmonary artery pressure
(mPAP)⩾ 25 mmHg. The current system of classiﬁcation identiﬁes
ﬁve major groups, which deﬁne treatment and prognosis.31,32 PAH
is a rare form of pulmonary hypertension due to a vasculopathy.
PAH complicating SSc has a poor prognosis signiﬁcantly worse
than idiopathic PAH32,33 and requires speciﬁc vascular
endothelium-targeted therapy. However, given the high preva-
lence of co-existing cardiac and lung disease, PH is also commonly
seen in SSc in the presence of pulmonary hypertension-left heart
disease (PH-LHD) and interstitial lung disease (PH-lung), where
treatment of pulmonary hypertension should be directed at the
underlying SSc-related heart or lung disease. Distinguishing these
forms of pulmonary hypertension can be challenging in SSc,
however, it is important not only in deﬁning treatment but also
survival. Indeed, patients with SSc and PH-lung have a worse
prognosis than other PAH patients33,34 while SSc patients with PH-
LD appear to have a signiﬁcantly better prognosis.32 A large meta-
analysis35 from a number of registries identiﬁed a 1-year survival
of 81% and 3-year survival of 52% in patients with SSc and PAH.
Depending on the method used to diagnose PAH, its prevalence
varies widely. However, using RHC as the gold standard, a meta-
analysis has calculated a prevalence of PAH in SSc of 9%.36
Screening for PAH in SSc with echocardiography is advocated
by the European Society of Cardiology and European Respiratory
Societies (ESC/ERS), who use tricuspid regurgitation velocity jet to
decide on the need for further investigation.37 However, a single
threshold at echocardiography cannot be used to conﬁdently
exclude PAH, because tricuspid regurgitation velocity is not always
present and/or can be eccentric leading to lower tricuspid
regurgitation velocity, and in some studies comparing RHC to
Doppler, tricuspid regurgitation velocity did not accurately reﬂect
invasive pressures.38 We and others have described the inaccura-
cies of echocardiographic systolic arterial pressure estimation.39,40
Furthermore, in the absence of lung disease, a signiﬁcantly
reduced free diffusion of carbon monoxide (DLCO) had high
speciﬁcity, but no threshold could be used to conﬁdently exclude
PAH.41 Consequently, a complex scoring system, DETECT has been
advocated as a screening tool for PAH in SSc38 and this study
reports a much higher sensitivity than echocardiography alone.
The DETECT algorithm missed 4% of PAH patients (false negatives),
but recommended RHC in 62% of patients while the strategy
following 2009 ESC/ERS guidelines37 missed 29% of diagnoses,
and required a RHC referral rate of 40%. A limitation of the
DETECT study is that this algorithm was only validated for patients
with a SSc diagnosis of43 years and a DLCOo60%. Therefore, it is
likely that the value of the proposed algorithm is less accurate for
those SSc patients with early rapidly progressive SSc within o4
years after onset of diagnosis, who are the best candidates
for AHSCT.
There is also increasing interest in the outcome of patients with
SSc who do not by strict criteria have pulmonary hypertension,
but have mPAP measured at basal RHC in the range
(21–24 mmHg). Two studies identiﬁed that between 31 and 55%
of these patients went on to develop resting PAH with a
signiﬁcant proportion doing so within 1 year of follow-up.42,43
These borderline patients will require careful assessment to
exclude left heart disease. If transplanted, careful follow-up in
prospective registries is important to ensure that they do not have
a high medium-term mortality risk related to the early develop-
ment of PAH. Given these uncertainties, there should be a low
threshold for performing RHC in SSc patients considered for
AHSCT. Performance of RHC appears a sensible mandatory
requirement to exclude or conﬁrm PAH in SSc patients considered
for AHSCT, since when using the current cyclophosphamide intense
transplant regimens, PAH is a contraindication to AHSCT.21,44
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Interstitial lung disease
ILD is common in SSc patients and almost a uniform ﬁnding at
post mortem.45 It ranges from a relatively limited and slowly
progressive condition seen most frequently in limited cutaneous-
SSc to a more ﬂorid, rapidly progressive form seen more
commonly dc-SSc. High resolution (HR) computed tomography
has revolutionized the identiﬁcation and clinical assessment of ILD
and is more sensitive than chest radiograph.46 A number of high-
resolution computed tomography patterns correlate with histolo-
gical changes: including: (i) non-speciﬁc interstitial pneumonia,
which is the most commonly observed and characterized by a
mixture of ground glass change and ﬁne reticular abnormalities
often extending sub-pleural to the medulla, (ii) usual interstitial
pneumonitis, characterized by sub-pleural reticular changes with
irregular linear opacities and cyst formation/honeycombing with
no or minimal ground glass change (iii) organizing pneumonia,
usually bilateral and consisting of areas of consolidation/nodular
change. Assessing the severity of lung disease to deﬁne clinical
course and help in decisions regarding the risk-beneﬁt ratio of
AHSCT can be challenging. Detailed assessment using volume CT
to evaluate the extent of lung disease plus lung function testing is
required to exclude patients at higher risk of TRM, but also
importantly to gain prospective data on potential treatment
beneﬁts.
HOW TO ASSESS CARDIOPULMONARY INVOLVEMENT IN SSC
PATIENTS BEFORE REFERRAL FOR TRANSPLANT
Transthoracic echocardiography
Although TTE, as routinely performed in SSc patient follow-up is
not without limitations, it provides important information
(Table 1).
Two-dimensional and M-mode echocardiographic ﬁndings that
should be investigated include (1) signiﬁcant LV or RV hyper-
trophy, (2) overt RV or LV wall motion abnormalities (including
diastolic interventricular septal bounce), (3) signiﬁcant pericardial
effusion, (4) RV systolic dysfunction and (5) LV systolic dysfunction.
Important Doppler ﬁndings on TTE that must be evaluated
further in SSc prior to AHSCT include the following: (1) any
hemodynamically signiﬁcant stenotic or regurgitant valvular
lesions, (2) elevated systolic arterial pressure, (3) notching in the
RV outﬂow tract pulse Doppler tracing, a sign of pulmonary
hypertension47 or (4) moderate or greater LV diastolic dysfunction
for the diagnosis and grading of LV diastolic dysfunction.48
Pulse wave tissue Doppler imaging of the lateral (anterior)
tricuspid annulus and septal and lateral mitral annulus should be
performed on all SSc patients undergoing evaluation for HSCT.
Tissue Doppler imaging evaluation of the RV (tricuspid annulus)
and LV (lateral mitral annulus) can provide important clues to the
diagnosis of RV and LV dysfunction, respectively.
Speckle-tracking echocardiography, a method for quantitating
myocardial mechanics that can detect subtle abnormalities in
myocyte calcium cycling and myocardial ﬁbrosis,49 is also an
important tool for analyzing subclinical myocardial dysfunction in
SSc.50 It remains to be seen whether speckle-tracking indices such
as global longitudinal strain and early diastolic strain rate of both
the LV and RV will be helpful beyond the other, more routine
testing (TTE, CMR and invasive hemodynamic testing with ﬂuid
challenge) that we currently recommend for pre-AHSCT evaluation
in the SSc patient.
Cardiac magnetic resonance imaging
CMR has emerged as the gold standard to assess right and left
ventricular systolic function (LVSF), myocardial ﬁbrosis and
pericardial disease. It provides important complementary informa-
tion not necessarily detected by TTE.51 In a consecutive series of
SSc patients, TTE detected abnormalities in only 45% when CMR
observed abnormalities in 75% of cases.51 In fact, in patients with
SSc, ECG, CMR and RHC without and with a ﬂuid challenge provide
independent assessments of cardiac response to stress and are all
required to adequately assess pre-AHSCT risk.
Ventricular morphology and function. Cine CMR is considered the
gold standard technique for quantifying ventricular mass, volumes
and function (Figures 1a and b). Without the need for contrast, the
high blood-myocardial signal difference improves endocardial
border deﬁnition resulting in superior inter-study reproducibility
for left ventricular volumes, function and mass when compared to
ECG.52 In 50 SSc patients free of cardiac symptoms, CMR detected
lower RV ejection fraction compared with controls, and lower RV
EF in dc-SSc compared with lc-SSc suggesting a role for CMR in
identifying subclinical RV dysfunction in SSc patients.53 Cine CMR
is the best method to detect diastolic ﬂattening of the
interventricular septum ‘D-sign’, an indicator of either right-
Table 1. Transthoracic echocardiography
Two-dimensional and M-mode
echocardiography
LV or RV hypertrophy LV mass index495 g/m2 in women or4115 g/m2 in men, or RV free wall
thickness in end-diastole 45 mm in the subcostal view.
RV or LV wall motion
abnormalities
Diastolic interventricular septal bounce (sign of ventricular
interdependence) or systolic or diastolic septal ﬂattening of the
interventricular septum (indicative of RV pressure or volume overload,
respectively).
Signiﬁcant pericardial effusion Diameter 41 cm at ventricular end-diastole.
RV systolic dysfunction RV fractional area change (apical 4-chamber view (RV end-diastolic area–
RV end-systolic area)/RV end-diastolic area) o35% or TAPSE o16 mm.
LV systolic dysfunction LV ejection fraction o55%.
Doppler echocardiography Signiﬁcant stenotic or
regurgitant valvular lesions
Deﬁned as greater than moderate per guideline deﬁnitions.56,59
Elevated pulmonary artery
systolic pressure
440 mmHg
Pulse wave TDI TDI evaluation of the RV
(tricuspid annulus)
RV TDI s’ velocity o10 cm/s is indicative of RV systolic dysfunction.62
TDI evaluation of the LV On the LV side, a lateral s’ velocity o8 cm/s is indicative of LV systolic
dysfunction. For evidence of LV diastolic dysfunction on TDI, it is helpful to
use age-speciﬁc cut-offs of lateral e’ velocity63 which have been used in
prior clinical trials: o10 cm/s if aged 45–54 years, o9 cm/s if aged
55–65 years or o8 cm/s if aged 465 years.65–68
Abbreviations: LV= left ventricle; RV= right ventricle; TAPSE= tricuspid annular plane systolic excursion; TDI= tissue Doppler imaging.
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Figure 1. (a, b) Cine CMR: A four chamber view (left) with positions of each slice of a short axis stack (right). Imaging is performed in the 2-
chamber, 3-chamber and 4-chamber long axis views and in a stack of short axis slices, typically acquired every 10 mm from the mitral valve
plane to the apex. Mass and volume are quantiﬁed from the short axis stack according to Simpson’s Rule by slice summation, which avoids
making any geometric assumptions about the shape of the ventricle. The high blood-myocardial contrast and ability to quantify volumes
without geometric assumptions is especially useful in the RV, because of its complex shape, abundant trabeculations and thin wall. Because
gadolinium contrast agents are conﬁned to the extracellular space, the change in T1 relaxation time is inversely related to the contrast agent
volume of distribution. Even without the administration of contrast, native T1 mapping detects prolongation of T1 in SSc. Active inﬂammation
can be assessed by T2-weighted images, which demonstrate increased signal in areas of myocardial edema. Abnormal myocardial T2 signal
has been described in patients with SSc.50 Endocardial (blue) and epicardial (yellow) borders are drawn, enabling calculation of left ventricular
mass and chamber volume according to Simpson’s rule.55 (c) Diastolic ﬂattening of interventricular septum, ‘D-sign’, visualized by cine CMR.
Adapted from Burt et al.22 http://www.jrheum.org/content/39/2/206.long, reproduced with permission from Journal of Rheumatology and
Richard Burt. (d) Focal ﬁbrosis in a SSc patient involving the mid and epicardial myocardium, sparing the subendocardium, as visualized by
LGE-CMR. Because gadolinium contrast agents are conﬁned to the extracellular space, the change in T1 relaxation time is inversely related to
the contrast agent volume of distribution. CMR measurement of the relative gadolinium concentration in the blood and myocardium, and the
direct measurement of the volume of distribution of gadolinium in the blood (1-hematocrit), enables calculation of extracellular volume
fraction (ECV), an index of the volume of distribution of contrast agent in the myocardium. Adapted from Burt et al.22 http://www.jrheum.org/
content/39/2/206.long,20 reproduced with permission from Journal of Rheumatology and Richard Burt. (e, f) Pericardial effusion seen as bright
white on Cine CMR (left) and dark black on phase sensitive inversion recovery LGE-CMR (right). Pericardial thickening and enhancement are
also seen on LGE-CMR. (g) Global subendocardial hypoperfusion in a SSc patient seen on adenosine stress CMR perfusion imaging.
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sided volume or pressure overload and elevated pulmonary
vascular resistance or in the absence of PH and of RV systolic
dysfunction with a constrictive and/or restrictive physiology
(Figure 1c).
Myocardial tissue characterization. Late gadolinium-enhanced
CMR (LGE-CMR) can accurately identify the presence, location,
size and morphology of irreversibly damaged myocardium.
Regions of focal myocardial ﬁbrosis become enhanced relative
to healthy myocardium several minutes after administration of a
gadolinium-based contrast agent (Figure 1d). In the chronic
setting, ﬁbrotic tissue has a larger interstitial space than normal
myocardium leading to a higher regional concentration of
extracellular contrast agent, more T1 shortening and brighter
signal. In SSc patients, focal myocardial ﬁbrosis may result from
recurrent vasospasm, ischemia–reperfusion injury and inﬂamma-
tion. Focal myocardial ﬁbrosis is frequently seen in SSc patients by
LGE-CMR (14% to 66%).51,56–58 In SSc autopsy studies, the
majority of myocardial ﬁbrosis was evident only on microscopic
examination.59 This type of diffuse ﬁbrosis may be underestimated
or even missed by LGE-CMR, which relies on differential contrast
uptake between diseased and normal myocardium. Newer
techniques employing T1 mapping now enable quantiﬁcation
of diffuse myocardial ﬁbrosis by calculating the myocardial
extracellular volume fraction.60
Pericardial disease is common in SSc and can include pericardial
effusion, pericarditis, cardiac tamponade and constrictive pericar-
ditis. Pericardial effusions are well seen both on cine and LGE
imaging (Figures 1e and f). Increased ventricular interdependence
is manifested as a ‘septal bounce’—early diastolic ﬂattening or
inversion of the interventricular septum seen during inspiration
followed by a right-sided septal shift during exhalation seen on
free breathing cine CMR.
Myocardial perfusion. SSc is often complicated by microvascular
coronary artery disease, which manifests as diffuse limitation in
vasodilator reserve. CMR ﬁrst-pass perfusion imaging has a higher
spatial resolution, and can detect subendocardial perfusion
defects that are below the resolution afforded by single-photon
Table 2. RHC with ﬂuid challenge
RA pressure tracing Kussmaul’s sign: abnormal rise in RA pressure during inspiration, reﬂective of an inability of the RV to handle increased
blood volume, which can be due to a non-compliant RV, a non-compliant pericardium (that is, constrictive pericarditis)
or signiﬁcant (typically severe) tricuspid regurgitation.
On the RV pressure tracing, a dip-and-plateau sign is indicative of either a non-compliant RV or constrictive pericarditis.
As is the case with the RA pressure tracing, a tall A wave at end-diastole in the RV pressure tracing is a sign of a
non-compliant RV.
PA pressure waveform A wide PA pulse pressure (PA systolic pressure–PA diastolic pressure) is a sign of increased PA stiffness.
PH is deﬁned as a mean PA pressure ⩾ 25 mmHg, while PAH is deﬁned as a mean PA pressure ⩾ 25 mmHg and
pulmonary arterial wedge pressure (PAWP) o15 mmHg (along with elevated pulmonary vascular resistance [PVR]43.0
Wood units). In patients with pulmonary venous hypertension (i.e., PH with PAWP ⩾ 15 mmHg), an elevated diastolic
pulmonary gradient (PA diastolic pressure – PCWP) 47 mmHg is a sign of combined post-capillary and pre-capillary.
Fluid challenge during
RHC
If RA pressure is ⩽ 12 mmHg and PAWP ⩽ 20 mmHg at rest, we recommend intravenous ﬂuid challenge with 10 cc/kg
warmed normal saline, infused over a 10-min period. The RA, PA and PAWP pressure should be measured, along with
the cardiac output, immediately after the ﬂuid challenge. Signs that demonstrate inability of the SSc patient to handle
a volume load include:
(1) RA pressure post 4PCWP post or ΔRA pressure 4ΔPCWP, which are signs of RV dysfunction.
(2) Increased mean PA pressure post 435 mmHg, increased PVR post 43 Wood units or increased DPG post
47 mmHg, which are indicative of stiff pulmonary vasculature.
(3) Increased PAWP post 425 mmHg, which is indicative of LV diastolic dysfunction.
(4) Unchanged or decreased cardiac output post, which is indicative of RV or LV dysfunction.
(5) Exaggerated dip-and-plateau pattern in the RV pressure tracing, which is a sign of restrictive or constrictive
physiology.
Abbreviations: DPG=diastolic pulmonary vascular pressure gradient; LV= left ventricle; PA=pulmonary artery; PAWP=pulmonary arterial wedge pressure;
PCWP=pulmonary capillary wedge pressure; PVR=pulmonary vascular resistance; RA= right atrial; RHC= right heart catheterization; RV= right ventricle;
SSc= systemic sclerosis.
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Cardiac catheterization with fluid
challenge
Figure 2. Flowchart for baseline evaluations and SSc patient
selection criteria prior to AHSCT.
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emission CT (SPECT; Figure 1g). In SSc patients treated with
nifedipine, the upslope ratio of CMR perfusion time–intensity
curves in the myocardium and blood (a semi-quantitative index
of myocardial perfusion) increased from baseline after 14 days
of treatment. Because the diffuse microvascular coronary
artery disease seen in SSc results in global reduction in
myocardial perfusion, quantiﬁcation of perfusion61 may provide
advantages over visual assessment and analysis techniques
that rely on relative perfusion differences between adjacent
segments.
Diastolic dysfunction. Advancements in CMR velocity encoding
techniques now allow accurate measurement of blood and
myocardial velocities. Emerging techniques enabling quantiﬁca-
tion of myocardial perfusion, myocardial diffuse ﬁbrosis and
diastolic dysfunction are likely to further enhance the utility of
CMR in the evaluation of SSc patients for AHSCT.
Right heart catheterization with ﬂuid challenge
RHC is considered the gold standard test for the diagnosis of
PAH,62 and is an essential part of the diagnostic work-up for both
Table 3. Baselines evaluation and SSc patient selection prior to HSCT according to ADWP consensus
Suggested baseline evaluations
History Complete history and examination including evaluation of quality of life by SHAQ-VAS, and/ or SF-36
questionnaires and of the extent of skin thickening by the mRSS.
Standard hematological,
biological and urinary
analyses and viral
serologies
Blood cell count, ESR.
Chemistry: electrolytes, renal and liver function tests, proteins, CK, BNP or NT-proBNP, troponin T or troponin I, CRP.
Urine: protein/creatinine ratio; urine analysis, casts.
Viral serologies: CMV, HSV, VZV, EBV, VDRL, HIV, (HTLV-1,2), Hepatitis B and C and autoantibody titers.
Immunology according to
EBMT/EULAR Consensus
Core Set
ANA, anti-Scl-70, anti-centromere and anti-polymerase RNA III antibodies (indicates high risk for renal crisis).
Immune-phenotyping by FACS of peripheral blood mononuclear cells = CD3+, CD4+, CD8+, CD4+ CD45RA, CD4+
CD45RO, CD31, CD3− CD56+ CD16+, CD19+, CD14+; IgG, IgA, IgM).
Biobanking: storage of plasma, serum, RNA, DNA.
Cardiopulmonary Chest X-ray, and exercise test (6MWT) is recommended.
ECG with rhythm strip, 24 h Holter monitoring in clinically symptomatic patients (for example, palpitations,
dizziness) or in those with rhythm abnormality on 12-lead ECG or rhythm strip.
Comprehensive TTE with Doppler and tissue Doppler imaging.
CMR with contrast and deep breathing cine images to evaluate for interventricular septal ﬂattening or bounce.
Invasive RHC including a ﬂuid challenge.
Contiguous and High resolution thoracic CT (or multi slice CT-scan with 6 HR section slices).
Pulmonary function studies (including TLC, VC, DLCO, DLCO/VA, RV).
Gastrointestinal For patients with history of GAVE or anemia or iron deﬁciency, endoscopy should be performed and vascular
ectasia, even if not actively bleeding, should undergo cauterization repeated on two or three occasions several
weeks later to prevent massive bleeding during transplant induced thrombocytopenia.
Suggested exclusion criteria for AHSCT in SSc using a cyclophosphamide-based regimen.
Age 465 years.
Pregnancy Pregnancy or unwillingness to use adequate contraception throughout investigation.
Psychiatric Psychiatric disease including alcohol or drug abuse.
Consent Inability to provide informed consent for treatment.
Liver function Twofold increase in liver transaminases or bilirubin.
Failure of synthetic function or evidence of cirrhosis.
Neoplasms Neoplasms myelodysplasia or serious hematological disorders contraindicating AHSCT.
Infection Active acute or chronic viral infection with HIV, HTLV-1,2, hepatitis B or C.
Heart LVEF o45%.
mPAP 425 mmHg or PASP 440 mmHg without ﬂuid challenge.
mPAP 430 mmHg or PASP 445 mmHg with 1000 cc NS infused over 10 min.
Diastolic septal ﬂattening (D-sign).
Septal bounce.
Constrictive pericarditis.
Cardiac tamponade.
Signiﬁcant atherosclerotic disease.
Arrhythmias that cannot be pharmacologically controlled, cardioverted or ablated.
Pulmonary FVC o65%.
DLCO-SB o40%.
Note: if pre-HSCT echocardiogram, CMR, and cardiac catheterization with and without ﬂuid challenge demonstrate
no contraindication, patients with lower DLCO and FVC may be considered candidates.
Patients should be strongly encouraged to stop smoking.
Renal SSc renal crisis in the previous 6 months.
Glomerular ﬁltration rate o40 mL/min/1.73 m2.
Note: patients with renal crises or renal failure may be considered candidates if blood pressure is well controlled
and dialysis is performed the morning following each cyclophophamide infusion, respectively.
Abbreviations: 6MWT= 6 minutes walking test; ADWP=Autoimmune Disease Working Party; AHSCT= autologous hematopoietic stem cell transplantation;
BNP= B-type natriuretic peptide; CMR= cardiac magnetic resonance; CT= computerized tomography; DLCO=diffusion of CO; DLCO/VA=KCO carbon
monoxide transfer coefﬁcient; ECG= electrocardiography; ESR= erythrocyte sedimentation rate; FVC= forced vital capacity; HR=high resolution;
HTLV=human T-lymphotropic virus; LVEF= left ventricular ejection fraction; mPAP=mean pulmonary artery pressure; mRSS=modiﬁed Rodnan skin score;
NT-proBNP=N-terminal pro-BNP; RV= residual volume; SSc= systemic sclerosis; TLC= total lung capacity; VA= alveolar volume; VC= vital capacity;
VDRL= venereal disease research laboratory test.
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PAH and constrictive pericarditis.63 Given the inability to reliably
exclude PAH using non-invasive techniques, all SSc patients
should undergo RHC during evaluation for AHSCT (Table 2), and
the test should be performed and interpreted by operators
experienced in hemodynamic testing. It is important to ensure
proper zeroing of the pressure transducer, and all pressures
should be measured at end-expiration (at which time intrathoracic
pressure is closest to zero).
On the right atrial (RA) pressure tracing, evidence of increased
RV stiffness includes a prominent A wave (reﬂecting increased
resistance to atrial contraction due to a non-compliant RV) and
increased RA pressure during inspiration (Kussmaul’s sign).
Prominent V waves on the RA pressure tracing indicate signiﬁcant
tricuspid regurgitation. If any of these signs is present on the RA
pressure tracing, the pre-transplant SSc patient should be further
evaluated to determine whether there is signiﬁcant RV ﬁbrosis,
primary RV failure, constrictive pericarditis or tricuspid regurgitation.
It is also helpful to analyze the PA pressure waveform on invasive
hemodynamic testing (Table 2). Evidence of PAH or combined post-
and pre-capillary PAH on RHC testing are absolute contraindications
for AHSCT in SSc. Patients with mild isolated pulmonary venous
hypertension can undergo diuresis with re-evaluation, although
these patients will be susceptible to adverse effects from ﬂuid
overload during AHSCT and should therefore be carefully evaluated
to exclude signiﬁcant LV systolic or diastolic dysfunction.
Fluid challenge during RHC is an important part of the pre-
AHSCT evaluation in SSc as a method for understanding the
cardiopulmonary response to increased volume. Although RHC is
considered to be a gold standard for hemodynamic assessment, it
only provides a snapshot of the patient at rest, and typically
occurs after fasting for 48 h. Since AHSCT involves the admin-
istration of a considerable volume load, ﬂuid challenge can be
very helpful to examine the response of the cardiopulmonary
system to increased volume in patients with SSc, and should be
performed in all patients in whom resting RA pressure
o12 mmHg and pulmonary capillary wedge pressure (PCWP)
o20 mmHg. An exaggerated rise in RA pressure, mean PA
pressure or PCWP, the emergence of a dip-and-plateau sign on RV
pressure tracing, and/or lack of augmentation of cardiac output
are all potential signs of a compromised SSc heart or pulmonary
vasculature in need of further assessment and could signify the
need to exclude patients from AHSCT.20,21
SSC PATIENT SELECTION CRITERIA AND PROCEDURES FOR
AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Referral criteria
Generally, patients should be considered for AHSCT if their age is
under 65 and onset of SSc within 5 years, although patients with
disease of up to 10 years duration have been transplanted without
increased risk, provided pre-cardiac assessment was normal. Best
candidates for AHSCT are patients within the ﬁrst 4 years of rapidly
progressive dc-SSc onset and a life-threatening condition with a
3–5 year survival, as well established by recent meta-analysis3 and
large EUSTAR prospective4 studies. Until more cardiac-safe non-
cyclophosphamide intensive regimens are developed, only
patients without evidence for PAH and sufﬁcient cardiopulmonary
function based on deﬁned selection criteria (Figure 2, Table 3) are
eligible for AHSCT.
Procedures of AHSCT
In October 2016, more than 2200 patients with autoimmune
diseases treated by AHSCT have been reported to the EBMT
database, including 440 patients with SSc, while 136 patients with
SSc have been transplanted in Chicago. AHSCT procedures
(mobilization, leukapheresis, conditioning, peripheral stem cell
infusion, supportive and post-transplant care) are detailed in
Table 4. Each center will follow its own local protocol for AHSCT
with regard to the risk/beneﬁt balance after careful standard
clinical and biological patient pre-transplant evaluation, whereas
the local treatment regimen and follow-up evaluation will be
recorded and analyzed according to ADPW guidelines.44,64
CONCLUSIONS
Recently published evidence in randomized controlled trials has
shown signiﬁcant improvement in organ function, quality of life,
disability and long-term survival. However, because of vital organ
Table 4. AHSCT procedures according to EBMT and international consensus
Mobilization and
Leukapheresis
PBSCs may be mobilized using either cyclophosphamide 2g/m2 infused in one session or 4g/m2 divided equally over 2
consecutive days followed by G-CSF 5–10 μg/kg/day and leukapheresis according to institutional protocols. A minimum of
3.0 × 106/kg CD34+ at harvest and freeze resulting in minimum 2.0 × 106/kg viable CD34+ cells is required for transplant.
Conditioning and
peripheral stem cell
infusion
Conditioning should not be initiated until at least 3–4 weeks of mobilization cyclophosphamide dose to minimize
accumulated acute cyclophosphamide myocardial injury.
Prior to conditioning a central venous catheter will be placed.
The current published conditioning regimen consists of cyclophosphamide 50 mg/kg/day intravenously for 4 consecutive
days (total 200 mg/kg) and rbATG (thymoglobulin) at total doses of 6.5–7.5 mg/kg, delivered according to institutional
protocols.
Given the potential of ATG-induced fever to destabilize patients, intravenous methylprednisolone 43–10 mg/kg will be
given to improve tolerability of the rbATG and decrease fever. ATG fever is also minimized by limiting the ﬁrst dose of ATG to
not more than 0.5 mg/kg.
The interval between the last dose of cyclophosphamide and infusion of the graft should be at least 48 h.
On day 0 stem cells are thawed and infused according to local standard operating procedures.
The minimum number of CD34+ cells reinfused should be 2× 106/kg, whether the graft is unselected or CD34+ selected.
Supportive care Supportive care measures, including prophylactic or therapeutic antibiotics, anti-viral, anti-pneumocystis and anti-fungal
agents, will be taken according to local standard operating procedures for such patients. Adherence to speciﬁc guidelines is
recommended (according to EBMT standards).
Transfusions will be given in accordance with local standard operating procedures for such patients. Based on current
transplantation-experiences in scleroderma patients, particular attention should be paid to thrombocytopenia, bleeding
tendency, hypo and hypertension, and respiratory insufﬁciency.
For both mobilization and conditioning, cyclophosphamide should be given with appropriate hydration and mesna
(to prevent hemorrhagic cystitis), but extreme care must be taken in ﬂuid balance management as patients are sensitive
to overload.
Abbreviations: AHSCT= autologous hematopoietic stem cell transplantation; EBMT= European Society for Blood and Marrow Transplantation; rbATG= rabbit
antithymocyte globulin.
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damage caused by SSc, the risks of transplant-related complica-
tions and treatment-related mortality risks have been relatively
high compared with other diseases. There is a need for more
thorough screening and evaluation of patients, as described
herein, to decrease the risk of transplant toxicity within specialized
centers of SSc-related transplant expertise.
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